Denmark's IO Vaccine Biotech Attracts Investor Interest
IO Biotech's Oversubscribed €127m Series B
Executive Summary
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
You may also be interested in...
Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
Merck & Co Takes Up Astex/Taiho SHP2 Program
Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.